SD Biotechnologies Balans Gezondheid
Financiële gezondheid criteriumcontroles 1/6
SD Biotechnologies has a total shareholder equity of ₩19.1B and total debt of ₩59.1B, which brings its debt-to-equity ratio to 308.7%. Its total assets and total liabilities are ₩100.0B and ₩80.8B respectively.
Belangrijke informatie
308.7%
Verhouding schuld/eigen vermogen
₩59.06b
Schuld
| Rente dekkingsratio | n/a |
| Contant | ₩4.83b |
| Aandelen | ₩19.13b |
| Totaal verplichtingen | ₩80.84b |
| Totaal activa | ₩99.97b |
Recente financiële gezondheidsupdates
Geen updates
Analyse van de financiële positie
Kortlopende schulden: A217480's short term assets (₩34.9B) do not cover its short term liabilities (₩78.6B).
Langlopende schulden: A217480's short term assets (₩34.9B) exceed its long term liabilities (₩2.3B).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: A217480's net debt to equity ratio (283.5%) is considered high.
Schuld verminderen: A217480's debt to equity ratio has increased from 8.3% to 308.7% over the past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: A217480 has less than a year of cash runway based on its current free cash flow.
Voorspelling contante baan: A217480 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 18.8% each year